Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Zydus unveils its ‘innovation and care’ centric corporate brand identity
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)